INmune Bio presents MINDFul Phase 2 baseline data; top-line results expected June 2025

Inmune Bio, Inc.

Poster at AD/PD conference details demographics: mean age 72.5 years, 69.2% APOE ε4 carriers.
64.9% of enrolled patients positive for >1 biomarker of immune dysfunction (hsCRP, ESR, HbA1C, APOE ε4).
Trial enrolled patients with MCI or mild AD; EMACC composite used as primary cognitive endpoint.
Screen failures driven mainly by MMSE inclusion criteria; enrollment completed November 2024.
Top-line results from the 24-week, randomized, placebo-controlled study expected in June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.